1 results match your criteria: "Harvard Institute Medical[Affiliation]"
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid.
Alzheimers Res Ther
March 2015
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School Boston, 77 Avenue Louis Pasteur, Harvard Institute Medical, Room 730, Boston, MA 02115 USA.
Introduction: Amyloid β-protein oligomers play a key role in Alzheimer's disease (AD), but well-validated assays that routinely detect them in cerebrospinal fluid (CSF) are just emerging. We sought to confirm and extend a recent study using the Singulex Erenna platform that reported increased mean CSF oligomer levels in AD.
Methods: We tested four antibody pairs and chose one pair that was particularly sensitive, using 1C22, our new oligomer-selective monoclonal antibody, for capture.